Interacting Drugs |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs CYP2C8 Substrates (High risk) |
Security Level |
|
Mechanism |
CYP2C8 Substrates (High risk): CYP2C8 Inducers (Highly Effective) may increase the metabolism of CYP2C8 Substrates (High risk). |
Management |
Monitor therapy |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs CYP2C8 Substrates (High risk)
Post Review about Hyoscyamine, atropine, scopolamine, and phenobarbital vs CYP2C8 Substrates (High risk) Click here to cancel reply.
Other Interactions of Hyoscyamine, atropine, scopolamine, and phenobarbital
Other Interactions of CYP2C8 Substrates (High risk)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.